Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-23T09:41:33.937Z Has data issue: false hasContentIssue false

DESVENLAFAXINE

Published online by Cambridge University Press:  03 May 2024

Stephen M. Stahl
Edited in association with
Jeffrey R. Strawn
Stephen M. Stahl
Affiliation:
University of California, San Diego
Jeffrey R. Strawn
Affiliation:
University of Cincinnati, Ohio
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Prescriber's Guide – Children and Adolescents
Stahl's Essential Psychopharmacology
 , pp. 183 - 192
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Atkinson, S, Lubaczewski, S, Ramaker, S et al. Desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2018;28(1):55–65.CrossRefGoogle ScholarPubMed
Bousman, CA, Stevenson, JM, Ramsey, LB et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther 2023;114(1):51–68.CrossRefGoogle ScholarPubMed
Brent, D, Emslie, G, Clarke, G et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008;299(8):901–13.CrossRefGoogle ScholarPubMed
Brent, DA, Emslie, GJ, Clarke, GN et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2009;166(4):418–26.CrossRefGoogle ScholarPubMed
Bridge, JA, Iyengar, S, Salary, CB et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297(15):1683–96.CrossRefGoogle ScholarPubMed
Croarkin, PE, Elmaadawi, AZ, Aaronson, ST et al. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. Neuropsychopharmacology 2021;46(2):462–9.CrossRefGoogle Scholar
Dobson, ET, Bloch, MH, Strawn, JR. Efficacy and tolerability of pharmacotherapy for pediatric anxiety disorders: a network meta-analysis. J Clin Psychiatry 2019;80(1):17r12064.CrossRefGoogle ScholarPubMed
Doroudgar, S, Perry, PJ, Lackey, GD et al. An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System. Hum Exp Toxicol 2016;35(7):767–74.CrossRefGoogle ScholarPubMed
Dwyer, JB, Stringaris, A, Brent, DA, Bloch, MH. Annual Research Review: Defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry 2020;61(3):312–32.CrossRefGoogle ScholarPubMed
Emslie, GJ, Findling, RL, Yeung, PP, Kunz, NR, Li, Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007;46(4):479–88.CrossRefGoogle ScholarPubMed
Findling, RL, Groark, J, Chiles, D et al. Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2014;24(4):201–9.CrossRefGoogle ScholarPubMed
Findling, RL, Groark, J, Tourian, KA et al. Pharmacokinetics and tolerability of single-ascending doses of desvenlafaxine administered to children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2016;26(10):909–21.CrossRefGoogle ScholarPubMed
Hathaway, EE, Walkup, JT, Strawn, JR. Antidepressant treatment duration in pediatric depressive and anxiety disorders: how long is long enough? Curr Probl Pediatr Adolesc Health Care 2018;48(2):31–9.Google Scholar
Mills, JA, Strawn, JR. Antidepressant tolerability in pediatric anxiety and obsessive-compulsive disorders: a Bayesian hierarchical modeling meta-analysis. J Am Acad Child Adolesc Psychiatry 2020;59(11):1240–51.CrossRefGoogle ScholarPubMed
Rynn, MA, Riddle, MA, Yeung, PP, Kunz, NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007;164(2):290–300.CrossRefGoogle ScholarPubMed
Sangkuhl, K, Stingl, JC, Turpeinen, M, Altman, RB, Klein, TE. PharmGKB summary: venlafaxine pathway. Pharmacogenet Genomics 2014;24(1):62–72.CrossRefGoogle ScholarPubMed
Strawn, JR, Lu, L, Peris, TS, Levine, A, Walkup, JT. Research review: pediatric anxiety disorders – what have we learnt in the last 10 years? J Child Psychol Psychiatry 2021 Feb;62(2):114–39.CrossRefGoogle Scholar
Strawn, JR, Mills, JA, Sauley, BA, Welge, JA. The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis. J Am Acad Child Adolesc Psychiatry 2018;57(4):235–44.e2CrossRefGoogle ScholarPubMed
Strawn, JR, Mills, JA, Poweleit, EA, Ramsey, LB, Croarkin, PE. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy 2023;43(7):675–90.CrossRefGoogle ScholarPubMed
Suresh, V, Mills, JA, Croarkin, PE, Strawn, JR. What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression. Depress Anxiety 2020;37(9):926–34.CrossRefGoogle ScholarPubMed
Weihs, KL, Murphy, W, Abbas, R, et al. Desvenlafaxine versus placebo in a fluoxetine-referenced study of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2018;28(1):36–46.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • DESVENLAFAXINE
  • Stephen M. Stahl, University of California, San Diego
  • Edited in association with Jeffrey R. Strawn, University of Cincinnati, Ohio
  • Book: Prescriber's Guide – Children and Adolescents
  • Online publication: 03 May 2024
  • Chapter DOI: https://doi.org/10.1017/9781009267526.020
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • DESVENLAFAXINE
  • Stephen M. Stahl, University of California, San Diego
  • Edited in association with Jeffrey R. Strawn, University of Cincinnati, Ohio
  • Book: Prescriber's Guide – Children and Adolescents
  • Online publication: 03 May 2024
  • Chapter DOI: https://doi.org/10.1017/9781009267526.020
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • DESVENLAFAXINE
  • Stephen M. Stahl, University of California, San Diego
  • Edited in association with Jeffrey R. Strawn, University of Cincinnati, Ohio
  • Book: Prescriber's Guide – Children and Adolescents
  • Online publication: 03 May 2024
  • Chapter DOI: https://doi.org/10.1017/9781009267526.020
Available formats
×